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PERSPECTIVE
What is the value of multidisciplinary care for
chronic kidney disease?
Richard J. Fluck1, Maarten W. Taal1,2*
1 Department of Renal Medicine, Royal Derby Hospital, Derby, United Kingdom, 2 Centre for Kidney
Research and Innovation, Division of Medical Sciences and Graduate Entry Medicine, University of
Nottingham, Derby, United Kingdom
* maarten.taal1@nhs.net
Chronic kidney disease (CKD) is associated with multiple biochemical and physiological
abnormalities as well as important adverse outcomes that include increased risk of cardiovas-
cular events (CVEs) [1], acute kidney injury (AKI) [2], and progression to end-stage kidney
disease (ESKD). These factors in turn impact negatively on quality of life and increase the bur-
den on healthcare resources. In this context, multidisciplinary care (MDC), advocating a holis-
tic approach to treatment, has the potential to improve care and reduce the risk of adverse
outcomes. Importantly, timely referral to multidisciplinary nephrology services allows effective
preparation for ESKD, including evaluation for kidney transplantation, dialysis modality selec-
tion, dialysis access planning, and financial, social, and psychological support. However, the
provision of MDC requires additional funding and personnel, and it is therefore vital that
advocates of MDC provide evidence of benefit and value to justify the additional cost. This is
particularly important because CKD consumes a disproportionate share of healthcare funding
globally due to the need for long-term care, a high rate of medical complications, and the high
cost of renal replacement therapy (RRT) [3].
The publication this week in PLOS Medicine of a comprehensive model to assess the cost-
effectiveness of MDC for patients with CKD, by Eugene Lin and colleagues [4], is therefore a
welcome development. The authors used data from published studies and Medicare claims in
the United States to develop a novel Markov model of CKD progression and used this to assess
the impact of a theoretical programme of MDC in mild to moderate CKD (estimated glomeru-
lar filtration rate [eGFR] 20–59 ml/min/1.73m2), with the intention of assessing the effective-
ness of MDC in slowing progression of CKD and reducing mortality. Predicted benefit was
measured as quality-adjusted life years (QALYs) gained. Overall, MDC was estimated to add
0.23 QALYs (95% CI 0.08–0.42) over usual care at a cost of US$51,285 per QALY gained,
within generally accepted cost-effectiveness thresholds for high-income countries. Robust sen-
sitivity testing showed that MDC remained cost-effective at a threshold of US$150,000 per
QALY gained, even when effectiveness was reduced to 25% or cost was increased 5-fold. This
analysis will be very useful to providers and those responsible for commissioning and funding
services seeking to implement MDC for CKD, but the paper also highlights important areas of
uncertainty that require further exploration.
First, what constitutes optimal MDC for CKD? In their analysis, the authors considered
MDC aimed at reducing CKD progression and made reasonable assumptions to include com-
ponents delivered by a nephrologist or advanced practitioner, a CKD educator, a dietician,
and a social worker. It is clear, however, that additional components could have been added,
including input from a pharmacist, a physiotherapist, an occupational therapist, or a
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psychologist. The optimal composition of MDC will likely vary with the stage and severity of
CKD as well as the target for improvement, but this remains to be determined. This consider-
ation is critical because each component adds cost and may have differing impact on the
benefits. In the National Health Service (NHS) in England, reimbursement for nephrology
outpatient attendance has an enhanced tariff payment for MDC. At present, this tariff applies
only to people with advanced CKD attending clinics intended to treat complications and pre-
pare them for RRT. The tariff does not specify the individual components of the service and
allows providers to determine their best configuration, but as yet, there has been no evaluation
against defined metrics. Further research is therefore required to evaluate the optimal and
most cost-effective composition of MDC for different stages of CKD.
Second, this paper illustrates that the cost-effectiveness of MDC varies with the risk profile
of patients. MDC was most cost-effective in patients with the highest level of albuminuria
because of their higher risk of CKD progression and, therefore, greater benefit from interven-
tion. Nevertheless, younger patients and, perhaps counterintuitively, those with less albumin-
uria achieved the greatest increase in QALYs, likely reflecting their longer life expectancy.
MDC remained cost-effective in these latter groups, though relatively more expensive because
care would have to continue longer to achieve benefit. Patients without albuminuria are at low
risk of progression to ESKD, and it is therefore likely that most of the benefit in this group
resulted from reduction in risk of cardiovascular death, a finding confirmed in a sensitivity
analysis that assumed no effect in reducing ESKD. These people would therefore benefit from
MDC focused on cardiovascular risk reduction and could be spared the components directed
at slowing CKD progression.
On the other hand, patients with advanced CKD would likely benefit from comprehensive
MDC to address complications such as anaemia and facilitate timely preparation for RRT.
Despite the robust findings of cost-effectiveness, it is likely that patients at low risk for CVEs
and ESKD will not benefit from MDC at all. These considerations illustrate the need to stratify
patients according to risk and develop packages of MDC that are best suited to their risk pro-
file and CKD stage. This would result in more cost-effective use of MDC and would reduce the
total cost burden. Components of MDC, particularly for lower-risk patients, would likely be
best delivered in primary care as part of broader chronic disease management programmes,
further lowering the cost.
Finally, the paper by Lin and colleagues focused on the benefit of MDC in reducing pro-
gression to ESKD and improving survival but did not consider potential improvement in sev-
eral other important outcomes, including CVEs, hospital admissions, and episodes of AKI. For
many patients with CKD, the risk of a CVE is substantially greater than the risk of progression
to ESKD, so this is an important consideration [1]. Additionally, the analysis did not consider
the impact on aspects likely to be of more immediate relevance to patients, including quality of
life, patient-reported outcome measures, and a patient’s level of engagement in care [5]. This is
largely because few studies evaluating these outcomes have been published and because cost-
effectiveness by these criteria is more difficult to assess, but ironically, it is in these areas that
MDC may afford the greatest benefit. Thus, Lin and colleagues’ study likely underestimated
the full value of MDC and highlights the need for more research to investigate benefit with
respect to all outcomes.
As acknowledged by the authors, this paper presents a theoretical model based on limited
currently available data, but the study provides robust evidence that MDC for CKD is cost-
effective, even with pessimistic assumptions. Much remains to be done to identify the optimal
package of care for different patient subgroups, but we agree with the authors that the data
provide sufficient evidence to support initiation of pilot MDC programmes as well as further
research to identify optimal models for implementation. Critically, future studies should
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collect metrics that comprehensively assess the benefit of MDC and that are aligned with inter-
national initiatives such as Standardised Outcomes in Nephrology (SONG) [6] (http://
songinitiative.org) and include patient-determined measures.
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